Home | Publications | Therapeutic | Vaccines place holder
place holder place holder

Vaccines

The Women's Health Market Outlook to 2011


Publication Date   April 2007
Publisher   Business Insights
Product Type   Strategic Report
Pages   224
ISBN Number   not applicable
Product Code   RBI138
Ask a question about this product?

Price £1,495.00

approximately: $2,961 | €1,900

Summary


With increased pricing pressure from generics, limited differentiation among new medicines and pipeline products and declining sales growth, the women's health market is facing threatening competitive forces, prompting major pharmaceutical players to initiate key strategic changes. 'The Women's Health Market Outlook to 2011' is a new report providing analysis of the current and future market for women's health drugs across all major indications. Forecasts are given based on current marketed portfolio, drivers and resistors of growth and R&D pipelines, enabling you to predict changes in the dynamics of the global women's health market. Key indications covered in this report are osteoporosis, infertility, uterine fibroids, endometriosis, urinary incontinence and gynecological infections.

Content


  • Executive Summary
    • Patient potential
    • Global market analysis
    • Competitive landscape
  • Chapter 1 Epidemiology Of Women's Health
    • Summary
    • Introduction
      • Osteoporosis
    • Overview
      • Diagnosis, treatment and management
      • Epidemiology
      • Forecast epidemiology
      • Hormonal Contraception
    • Overview
      • Prescription and management
      • Epidemiology
      • Forecast epidemiology
      • Urinary Incontinence
    • Overview
      • Diagnosis, treatment and management
      • Epidemiology
      • Forecast epidemiology
      • Common gynecological infections
    • Overview
      • Candidiasis
      • Vaginosis
      • Trichomoniasis
      • Diagnosis, treatment and management
      • Epidemiology
      • Forecast epidemiology
      • Hormone replacement therapies
    • Overview
      • Diagnosis, treatment and management
      • Epidemiology
      • Forecast epidemiology
  • Chapter 2 Global Market Analysis
    • Summary
    • Introduction
      • Market analysis by country
      • Licensing trends
      • Market analysis by drug class
      • Leading brands dynamics
    • Key events in the market
      • Bayer acquires Schering AG to form Bayer-Schering Pharma
      • Safety concerns associated with the use of transdermal release system formulations of hormonal contraceptives
    • Association of jaw bone necrosis with the long term use of bisphosphonatesin the treatment of osteoporosis
      • Arrival of generic competition to market-leading anti-infectives treatments
      • Launch of Plan B emergency contraceptive in the US market
      • Urinary incontinence market analysis
    • Market dynamics
      • Key brands analysis
      • Urinary incontinence sales forecasts to 2011
      • Anti-infectives market analysis
      • Market dynamics
    • Key brands analysis
      • Anti-infectives sales forecasts to 2011
      • Osteoporosis
      • Leading brands of Osteoporosis market
      • Competitive dynamics of subclasses of osteoporosis treatments
      • Bisphosphonates market analysis
    • Market dynamics
      • Key brands analysis
      • Calcitonins
      • Market dynamics
    • Key brands analysis
      • Osteoporosis sales forecasts to 2012
      • Hormonal contraception
      • Competitive dynamics of subclasses of hormonal contraceptives
      • Leading brands of Hormonal Contraceptives
    • Key brands analysis
    • Hormonal contraceptives sales forecasts to 2012
      • Hormone Replacement Therapy
      • Competitive dynamics of subclasses of the Hormone Replacement Therapy market
      • Leading brands of Hormone replacement therapies
    • Market dynamics
      • Key brands analysis
      • Hormonal replacement therapy sales forecasts to 2012
      • Total Women's health market sales forecasts to 2011
  • Chapter 3 Pipeline Analysis
    • Summary
    • Introduction
      • Key trends in R&D
      • New drug delivery formulations
      • Reformulations
      • Extended cycle regimes
      • New dosing regime
      • Second-generation anticholinergics in urinary incontinence
      • The women's health pipeline
      • Leading drugs in development
      • Profiles of key pipeline products
    • Phase II compounds
      • NBI-56418
      • Nesterone
      • Phase III compounds
      • J867 (asoprisnil)
      • Org 36286 (corifollitropin alfa )
      • Drugs in registration
      • Pristiq (desvenlafaxine)
      • Viviant (bazedoxifene)
      • Evamist (estradiol MDTS)
      • Lybrel/Librel/Anya (levonorgestrel/ethinyl estradiol)
      • Recently marketed drugs
      • Seasonique (levonorgestrel/ethinyl estradiol)
      • Boniva (ibandronate)
      • Yaz (drosperinone/ethinyl estradiol)
      • Novel anticholinergic treatments
      • Pipeline forecasts
      • Contraception forecasts
      • Osteoporosis forecasts
      • Hormone replacement forecasts
      • Urinary incontinence forecasts
      • Anti-infectives forecasts
      • Key trends
  • Chapter 4 Competitive Landscape
    • Summary
      • Introduction
      • Company market shares
      • Merck
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Novartis
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Bayer-Schering Pharma
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Procter & Gamble
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Wyeth
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Pfizer
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Johnson & Johnson
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Akzo Nobel/Organon
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Barr
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Watson
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
  • Chapter 5 Appendix
    • IMS data
      • G1 Anti-infectives
      • G3 Hormonal contraceptives
      • H4 and M5 Osteoporosis
      • G3 Hormone replacement therapy
      • G2 Urinary incontinence
      • G2 Others
  • List Of Figures
    • Figure 1.1: Typical treatment patterns in the treatment of osteoporosis
    • Figure 1.2: Typical treatment patterns in the treatment of urinary incontinence
    • Figure 2.3: Global women's health market share by geography, 2005
    • Figure 2.4: Sales of types of women's health brands, 2004-05
    • Figure 2.5: Competitive dynamics of the global women's health market by drug class, 2005
    • Figure 2.6: Competitive dynamics of the leading 10 brands in the global women's health market,
    • Figure 2.7: Competitive dynamics of subclasses of osteoporosis treatments, 2004-5
    • Figure 2.8: Competitive dynamics of the leading osteoporosis treatments in the global women's health market, 2004-5
    • Figure 2.9: Competitive dynamics of subclasses of hormonal contraceptives, 2004-5
    • Figure 2.10: Competitive dynamics of the leading hormonal contraceptive brands in the global women's health market, 2004-5
    • Figure 2.11: Competitive dynamics of subclasses of the global HRT market, 2004-5
    • Figure 3.12: Prevailing R&D approaches, 2006
    • Figure 3.13: The women's health pipeline by indication and stage of development, 2006
    • Figure 3.14: Leading recently launched products and late-stage R&D compounds in the women's health market, 2005
    • Figure 4.15: Competitive dynamics of the leading players in the global women's health market,
    • Figure 4.16: Merck's women's health sales, 2005
    • Figure 4.17: Novartis' women's health sales, 2005
    • Figure 4.18: Bayer-Schering Pharma's women's health sales, 2005
    • Figure 4.19: P&G's women's health sales, 2005
    • Figure 4.20: Wyeth's women's health sales, 2005
    • Figure 4.21: Pfizer's women's health sales, 2005
    • Figure 4.22: J&J's women's health portfolio sales, 2005
    • Figure 4.23: Akzo Nobel/Organon's women's health portfolio sales, 2005
    • Figure 4.24: Barr's women's health portfolio sales, 2005
    • Figure 4.25: Watson's women's health portfolio sales, 2005
  • List Of Tables
    • Table 1.1 Estimated prevalence of women's health conditions in the seven major pharmaceutical markets, 2005
    • Table 1.2 Estimated prevalence of hip fractures use across seven major markets, 2005
    • Table 1.3 Forecast epidemiology of hip fractures across the seven major markets, 2005-11
    • Table 1.4: Estimated prevalence of hormonal contraception across seven major markets, 2005
    • Table 1.5: Forecast prevalent rates for epidemiology of contraceptive use across the seven major markets, 2005-11
    • Table 1.6: Estimated prevalence of urinary incontinence use across seven major markets, 2005
    • Table 1.7: Forecast epidemiology of urinary incontinence across the seven major markets
    • Table 1.8: Estimated point prevalence of candidiasis across seven major markets, 2005
    • Table 1.9: Estimated point prevalence of vaginosis across seven major markets, 2005
    • Table 1.10: Estimated prevalence of trichomoniasis across seven major markets, 2005
    • Table 1.11: Forecast epidemiology of candidiasis across the seven major markets, 2005-11
    • Table 1.12: Forecast epidemiology of trichomoniasis across the seven major markets, 2005-11
    • Table 1.13: Forecast epidemiology of vaginosis across the seven major markets, 2005-11
    • Table 1.14: Estimated incidence of menopause among women across seven major markets,
    • Table 1.15: Combined estimated incidence of hysterectomies and fibroids among women across seven major markets, 2005
    • Table 1.16: Forecast epidemiology of menopause across the seven major markets, 2005-11
    • Table 1.17: Forecast epidemiology of hysterectomies and fibroids across the seven major markets,2005-11
    • Table 2.18: Breakdown of the global women's health market by drug class, 2001-05
    • Table 2.19: Leading brands in the global women's health market, 2004-05
    • Table 2.20: Leading urinary incontinence brands in the global women's health market, 2004-05
    • Table 2.21: Urinary incontinence sales forecast, 2005-11
    • Table 2.22: Leading anti-infectives brands in the global women's health market, 2004-05
    • Table 2.23: Anti-infectives sales forecast, 2005-11
    • Table 2.24: Breakdown of osteoporosis market by drug class, 2001-05
    • Table 2.25: Leading osteoporosis brands in the global women's health market, 2004-05
    • Table 2.26: Leading bisphosphonate brands in the global women's health market, 2004-05
    • Table 2.27: Leading calcitonin brands in the global women's health market, 2004-05
    • Table 2.28: Osteoporosis sales forecast, 2005-11
    • Table 2.29: Breakdown of hormonal contraception market by drug class, 2001-05
    • Table 2.30: Leading hormonal contraceptive brands in the global women's health market, 2004-
    • Table 2.31: Hormonal contraceptive sales forecast, 2005-11
    • Table 2.32: Breakdown of hormone replacement therapy market by drug class, 2001-05
    • Table 2.33: Leading HRT brands in the global women's health market, 2004-05
    • Table 2.34: HRT sales forecast, 2005-11
    • Table 2.35: Therapeutic sales forecasts by drug class, 2005-11
    • Table 3.36: Contraception pipeline sales forecasts, 2005-11
    • Table 3.37: Osteoporosis pipeline sales forecasts, 2005-11
    • Table 3.38: HRT pipeline sales forecasts, 2005-11
    • Table 3.39: Urinary incontinence pipeline sales forecasts, 2005-11
    • Table 4.40: Leading players in the global women's health market, 2004-5
    • Table 4.41: Merck women's health product portfolio, 2004-5
    • Table 4.42: Novartis' women's health product portfolio, 2004-5
    • Table 4.43: Bayer-Schering Pharma's women's health product portfolio, 2004-5
    • Table 4.44: Bayer-Schering Pharma's women's health R&D product pipeline, 2006
    • Table 4.45: P&G's women's health product portfolio, 2004-5
    • Table 4.46: Wyeth's women's health product portfolio, 2004-5
    • Table 4.47: Wyeth's women's health R&D product pipeline, 2006
    • Table 4.48: Pfizer's women's health product portfolio, 2004-5
    • Table 4.49: Pfizer's women's health R&D product pipeline, 2006
    • Table 4.50: J&J's women's health product portfolio, 2004-5
    • Table 4.51: Akzo Nobel/Organon's women's health product portfolio, 2004-5
    • Table 4.52: Akzo Nobel/Organon's R&D product pipeline, 2005
    • Table 4.53: Barr's women's health product portfolio, 2004-5
    • Table 4.54: Watson's women's health product portfolio, 2004-5
    • Table 4.55: Watson's R&D product pipeline, 2005